| Name | Title | Contact Details |
|---|---|---|
David Vega |
Vice President of Operations Analysis and Compliance | Profile |
E P Radiological Svc is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Savista is a prominent provider of healthcare revenue cycle management services. Savista partners with healthcare organizations to problem solve and deliver revenue cycle improvement services that enable their success, support their patients, and nurture their communities. We integrate knowledge and expertise of the revenue cycle to provide financial and operational performance benefits for healthcare organizations of any size. Our global organization of 4,000 colleagues partners with more than 330 US-based healthcare clients, delivering custom solutions to help solve their business challenges.
Mada is a manufacturer of several hundred Medical, Dental, Podiatric and Veterinary products catering to the Home Healthcare and Institutional markets. Mada was incorporated in 1969, with Production and Corporate Offices located in Carlstadt, New Jersey
Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options. Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible. Massive Bio translates the world-class oncology knowledge of the large cancer centers experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.